Recon: FDA advisors back OTC switch for naloxone; Grifols to lay off 2,000 US staff
ReconJoanne S. Eglovitch
BiologicsDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReconJoanne S. EglovitchBiologicsDiagnosticsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy